Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

(1989): Jones AP+, Br J Cancer 59, 814 (1985): Levine LE+, Arch Dermatol 121, 102 (1985): Vogelzang NJ+, AnnInternMed103, 303 (1985): Walker IR+, Arch Dermatol 121, 1240 (1984): Lokich JJ+, AnnInternMed101, 798 (1982): Cordonnier C+, AnnInternMed97, 783 Inflammation (2005): Ilyas EN+, Cutis 75, 167 Intertrigo (2006): Campanelli A+, J Eur Acad Dermatol Venereol 20(8), 1022 (2006): Korver GE+, J Drugs Dermatol 5(9), 901 (2000): Lotem M+, Arch Dermatol 136, 1475 Keratoderma Melanosis (2000): Lotem M+, Arch Dermatol 136, 1475 Necrosis (local) (2006): Palaia I+, Am J Obstet Gynecol 195(4), e1 (distal phalange) (1998): Bekerecioglu M+, JSurgRes75, 61 (1982): Riegels-Nielsen P+, Ugeskr-Laeger (Danish) 144, 1313 (1981): von Eyben FE+, Cancer 48, 1535 (passim) Palmar–plantar erythema (painful) (1990): Pagliuca A+, Postgrad Med J 66, 242 (1989): Jones AP+, Br J Cancer 59, 814 (1989): Oksenhendler E+, Eur J Cancer Clin Oncol 25, 1181 (1988): Shall L+, Br J Dermatol 119, 249 Palmar–plantar toxicity (2004): Chua SL+, Neuro-oncol 6(1), 38 (4%) Photo-recall (10%) (2006): Selleri S+, J Invest Dermatol (2004): Martin M+, Clin Breast Cancer 5(5), 353 (53%) (with vinorelbine) (2000): Lotem M+, Arch Dermatol 136, 1475 (passim) (1995): Bonadonna G+, JAMA 273, 542 (96%) (1994): Bogner JR+, J Acquir Immune Defic Syndr 7, 463 (1994): Rodrigeuz R+, Ann Oncol 5, 769 (1989): Henderson IC+, J Clin Oncol 7, 560 (>5%) (1988): Giaccone G+, Cancer Nurs 11, 170 (1986): Martin-Jiminez M+, NEnglJMed315, 894 (1986): Perez JE+, Cancer Treat Rep 70, 1213 (1984): Satterwhite B+, Cancer 54, 34 (1984): Wheelock JB+, Cancer Treat Rep 68, 1387 (1983): Howard N+, Br J Radiol 56, 963 (1983): Tigges FJ, MMW Munch Med Wochenschr (German) 125, 19 (1982): Gregory RP+, Br Med J Clin Res Ed 284, 1674 (1982): Hunt JM+, Cancer Nurs 5, 25 (1981): Anderson JE+, Br Med J Clin Res 282, 423 (1981): Cooke T+, Br Med J Clin Res Ed 282, 734 (1981): Hallett N, Nurs Mirror 152, 32 (1981): Tigges FJ, MMW Munch Med Wochenschr (German) 123, 737 (1980): Presser SE, NEnglJMed302, 921 (1980): Timothy AR+, Lancet 1, 663 Nails Nails – Beau’s lines (transverse nail bands)

194 DOXORUBICIN (2006): Dasanu CA+, Dermatol Online J 12(6), 10 (with vincristine and dexamethasone) (1994): Ben-Dayan D+, Acta Haematol 91, 89 Nails – melanonychia (2003): Khairkar PH, Indian Pediatr 40(11), 1094 Nails – Muehrcke’s lines (2006): Dasanu CA+, Dermatol Online J 12(6), 10 (with vincristine and dexamethasone) Nails – onycholysis (1990): Curran CF, Arch Dermatol 126, 1244 (1989): Jones AP+, Br J Cancer 59, 814 (1985): Kechijian P, JAmAcadDermatol12, 552 (1980): Runne U+, ZHaut(German) 55, 1590 Nails – pigmentation (2006): Dasanu CA+, Dermatol Online J 12(6), 10 (with vincristine and dexamethasone) (1999): Ghoshal UC+, J Diarrhoeal Dis Res 17, 43 (1983): Bronner AK+, JAmAcadDermatol9, 645 (1983): James WD+, Arch Dermatol 119, 334 (white lines) (1983): Manigand G+, Sem Hop (French) 59, 1840 (1982): Sans-Ortiz J+, Med Clin (Barc) (Spanish) 79, 49 (1981): Giacobetti R+, Am J Dis Child 135, 317 (1980): Runne U+, ZHaut(German) 55, 1590 (1980): Sulis E+, Eur J Cancer 16, 1517 Other Anaphylactoid reactions/Anaphylaxis (5%) Injection-site extravasation (>10%) (2000): Kassner E, JPediatrOnconNurs17, 135 (2000): Lotem M+, Arch Dermatol 136, 1475 (1999): Fleming A+, JHandSurg[Br]24, 390 (1998): Emiroglu M+, Ann Plast Surg 41, 103 (1989): Harwood KV+, Oncol Nurs Forum 16, 10 (1984): Hankin FM+, J Pediatr Orthop 4, 96 (1984): Sonneveld P+, Cancer Treat Rep 68, 895 (1983): Cohen FJ+, JHandSurgAm8, 43 (1983): Olver IN+, Cancer Treat Rep 67, 407 (1983): Pitkanen J+, JSurgOncol23, 259 (1980): Barden GA, South Med J 73, 1543 Injection-site necrosis (>10%) (1998): Bekerecioglu M+, JSurgRes75, 61 (1987): Dufresne RG, Cutis 39, 197 (1983): Bronner AK+, JAmAcadDermatol9, 645 Injection-site reactions (2001): Verschraegen CF+, Cancer 92(9), 2327 Injection-site ulceration (>10%) Myalgia/Myositis/Myopathy/Myotoxicity (2002): Cantu MG+, J Clin Oncol 20(5), 1232 (4%) (with cyclophosphamide and cisplatin) DOXYCYCLINE Trade names: Adoxa (Bioglan); Apo-Dox; Apo-Doxy; Atridox; Azudoxat; Bactidox; Doryx (Warner Chilcott); Doximed; Doxy- 100; Doxylin; Doxytec; Monodox; Vibra-Tabs (Pfizer); Vibramycin (Pfizer); Vibramycine; Vibravenos Indications: Various infections caused by susceptible organisms Category: Antibiotic, tetracycline Half-life: 12–22 hours Clinically important, potentially hazardous interactions with: amoxicillin, ampicillin, antacids, bacampicillin, bismuth, calcium, carbenicillin, cloxacillin, corticosteroids, digoxin, iron, methoxyflurane, mezlocillin, nafcillin, oxacillin, penicillins, piperacillin, retinoids, ticarcillin, zinc Reactions Skin Actinic granuloma (2003): Lim DS+, Australas J Dermatol 44(1), 67 Acute generalized exanthematous pustulosis (AGEP) (1993): Trueb RM+, Dermatology 186, 75 Allergic reactions (sic) (0.47%) (1986): Bigby M+, JAMA 256, 3358 Angioedema (1997): Shapiro LE+, Arch Dermatol 133, 1224 Erythema multiforme (1988): Lewis-Jones MS+, Clin Exp Dermatol 13, 245 (1987): Curley RK+, Clin Exp Dermatol 12, 124 (1985): Albengres E+, Therapie (French) 38, 577 Erythroderma (2003): Batinac T+, Tumori 89(1), 91 Exanthems (2003): Batinac T+, Tumori 89(1), 91 (1987): Bryant SG+, Pharmacotherapy 7, 125 (4.4%) Exfoliative dermatitis Fixed eruption (

(1989): Jones AP+, Br J Cancer 59, 814<br />

(1985): Levine LE+, Arch Dermatol 121, 102<br />

(1985): Vogelzang NJ+, AnnInternMed103, 303<br />

(1985): Walker IR+, Arch Dermatol 121, 1240<br />

(1984): Lokich JJ+, AnnInternMed101, 798<br />

(1982): Cordonnier C+, AnnInternMed97, 783<br />

Inflammation<br />

(2005): Ilyas EN+, Cutis 75, 167<br />

Intertrigo<br />

(2006): Campanelli A+, J Eur Acad Dermatol Venereol 20(8), 1022<br />

(2006): Korver GE+, J <strong>Drug</strong>s Dermatol 5(9), 901<br />

(2000): Lotem M+, Arch Dermatol 136, 1475<br />

Keratoderma<br />

Melanosis<br />

(2000): Lotem M+, Arch Dermatol 136, 1475<br />

Necrosis (local)<br />

(2006): Palaia I+, Am J Obstet Gynecol 195(4), e1 (distal<br />

phalange)<br />

(1998): Bekerecioglu M+, JSurgRes75, 61<br />

(1982): Riegels-Nielsen P+, Ugeskr-Laeger (Danish) 144, 1313<br />

(1981): von Eyben FE+, Cancer 48, 1535 (passim)<br />

Palmar–plantar erythema (painful)<br />

(1990): Pagliuca A+, Postgrad Med J 66, 242<br />

(1989): Jones AP+, Br J Cancer 59, 814<br />

(1989): Oksenhendler E+, Eur J Cancer Clin Oncol 25, 1181<br />

(1988): Shall L+, Br J Dermatol 119, 249<br />

Palmar–plantar toxicity<br />

(2004): Chua SL+, Neuro-oncol 6(1), 38 (4%)<br />

Photo-recall (10%)<br />

(2006): Selleri S+, J Invest Dermatol<br />

(2004): Martin M+, Clin Breast Cancer 5(5), 353 (53%) (with<br />

vinorelbine)<br />

(2000): Lotem M+, Arch Dermatol 136, 1475 (passim)<br />

(1995): Bonadonna G+, JAMA 273, 542 (96%)<br />

(1994): Bogner JR+, J Acquir Immune Defic Syndr 7, 463<br />

(1994): Rodrigeuz R+, Ann Oncol 5, 769<br />

(1989): Henderson IC+, J Clin Oncol 7, 560 (>5%)<br />

(1988): Giaccone G+, Cancer Nurs 11, 170<br />

(1986): Martin-Jiminez M+, NEnglJMed315, 894<br />

(1986): Perez JE+, Cancer Treat Rep 70, 1213<br />

(1984): Satterwhite B+, Cancer 54, 34<br />

(1984): Wheelock JB+, Cancer Treat Rep 68, 1387<br />

(1983): Howard N+, Br J Radiol 56, 963<br />

(1983): Tigges FJ, MMW Munch Med Wochenschr (German)<br />

125, 19<br />

(1982): Gregory RP+, Br Med J Clin Res Ed 284, 1674<br />

(1982): Hunt JM+, Cancer Nurs 5, 25<br />

(1981): Anderson JE+, Br Med J Clin Res 282, 423<br />

(1981): Cooke T+, Br Med J Clin Res Ed 282, 734<br />

(1981): Hallett N, Nurs Mirror 152, 32<br />

(1981): Tigges FJ, MMW Munch Med Wochenschr (German)<br />

123, 737<br />

(1980): Presser SE, NEnglJMed302, 921<br />

(1980): Timothy AR+, Lancet 1, 663<br />

Nails<br />

Nails – Beau’s lines (transverse nail b<strong>and</strong>s)

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!